March 17, 2011Heart
Prognostic value of mid-regional pro-adrenomedullin in patients with heart failure after an acute myocardial infarction
Why the study?
Does mid-regional pro-adrenomedullin (MR-proADM) improve prognostic prediction compared to BNP and NT-proBNP in patients with heart failure after an acute myocardial infarction?
Population
214 patients from the OPTIMAAL study who developed signs and/or symptoms of heart failure or a left…
Comparison
Measurement of mid-regional pro-adrenomedullin… vs B-type natriuretic peptide and N-terminal…
Design
Cohort
Follow-up
mean 918±311 days
Authors
Discussion
Loading...
Member takes
Implication
MR-proADM may enhance mortality prediction in post-AMI HF beyond natriuretic peptides; leaves open prospective validation before clinical adoption.
Structured PICO
Does mid-regional pro-adrenomedullin (MR-proADM) improve prognostic prediction compared to BNP and NT-proBNP in patients with heart failure after an acute myocardial infarction?
P
Population
214 patients from the OPTIMAAL study who developed signs and/or symptoms of heart failure or a left ventricular ejection fraction <0.35% after an acute myocardial infarction, mean age 68±10 years.
I
Intervention
Measurement of mid-regional pro-adrenomedullin (MR-proADM) at a median of 3 days after acute myocardial infarction
C
Comparator
B-type natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP)
O
Outcome
All-cause mortality and a composite end point including death, myocardial reinfarction, stroke and/or resuscitated cardiac arrestcomposite
MR-proADM is a strong prognostic biomarker for mortality and morbidity in patients with heart failure post-AMI, demonstrating superior predictive value compared to standard biomarkers BNP and NT-proBNP.
Cite This Study
Klip et al. (2011) studied this question.